FirstIgnite is supporting the commercialization of Stony Brook University’s monoclonal antibody technology, which targets wzi29, a major capsular polysaccharide (CPS) expressed by carbapenem-resistant Klebsiella pneumoniae (CR-Kp), providing a therapy for the heterogeneous CPS serotypes of CR-Kp. The technology shows cross-reactivity and efficacy against three most prevalent CR-Kp types, is effective both pre- and 4 hours post-infection, and reduces CR-Kp lung burden and dissemination.
This technology is applicable to the treatment of Klebsiella infections. The bacterial infection market was worth $ 72.0 billion in 2021 and is expected to increase to $138.28 billion by 2029.
Stony Brook University’s monoclonal antibody technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Stony Brook University team, you can schedule a time directly on their team’s calendar here.